Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HMK received grant support from Amgen, Pfizer, Bristol-Myers Squibb (BMS), Novartis Pharmaceuticals, and Ariad Pharmaceuticals. ACL received research funding from Autolus, Amphivena, Astellas, Jazz, Kadmon, Kite, Pharmacyclics, and Talaris; consulting fees from AbbVie, Amgen, BMS, and Pfizer; and participated in a data safety monitoring board for Servier. FZ and YZ are employees and hold stocks of Amgen Inc. NG served on an advisory board for Kite Pharma (uncompensated), received fees for serving on advisory boards from Amgen, Pfizer, and Celgene/Juno Therapeutics, received travel support from Amgen and Pfizer, and received grant support from Amgen. RB served as an advisor and received honoraria from Amgen, Cellex, GEMoaB, AstraZeneca, Novartis, and CatalYm; in addition, RB has a patent for blinatumomab with royalties paid. GZ is an employee of, has patents from, and owns stock in Amgen Inc. FL has received personal fees from Amgen, personal fees from Novartis, other from Bellicum Pharmaceutical, other from Neovii, personal fees from Miltenyi, personal fees from Medac, personal fees from Jazz Pharmaceutical, and personal fees from Takeda, outside the submitted work."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by Amgen Inc."